Decernotinib

From WikiMD.org
Jump to navigation Jump to search

Decernotinib

Decernotinib (pronunciation: de-ser-no-ti-nib) is an experimental drug that was being developed for the treatment of rheumatoid arthritis. It is a selective inhibitor of Janus kinase 3 (JAK3), a type of enzyme that plays a crucial role in the signaling pathways of various immune cells.

Etymology

The name "Decernotinib" is derived from the Latin word "decerno" which means "to decide" or "to determine", and "tinib", a common suffix for tyrosine kinase inhibitors.

Pharmacology

Decernotinib works by selectively inhibiting the activity of JAK3, thereby reducing the inflammatory response that is characteristic of rheumatoid arthritis. This makes it a potential therapeutic option for patients with this condition.

Clinical Trials

Decernotinib has undergone Phase II clinical trials for the treatment of rheumatoid arthritis. However, the development of the drug was discontinued due to safety concerns.

Related Terms

External links

Esculaap.svg

This WikiMD dictionary article is a stub. You can help make it a full article.


Languages: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, Urdu, বাংলা, తెలుగు, தமிழ், ಕನ್ನಡ,
Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, European español, Deutsch, français, русский, português do Brasil, Italian, polski